Product Name:(S)-3-Phenyl-2-(pyrazine-2-carboxamido)propanoic acid
IUPAC Name:(2S)-3-phenyl-2-[(pyrazin-2-yl)formamido]propanoic acid
| Packing Unit | Available Stock | Price($) | Quantity |
|---|---|---|---|
| CM168810-100g | in stock | ȃIJƓ |
|
|
|||
| Product Overview |
(S)-3-Phenyl-2-(pyrazine-2-carboxamido)propanoic acid, also known as (S)-3-Phenyl-2-pyrazinamide (SPP), is a carboxamide derivative of pyrazine and a structural analog of the common anti-diabetic drug metformin. SPP has been studied for its potential therapeutic applications in the treatment of type 2 diabetes, obesity, cancer, and other metabolic diseases. |
| Synthesis and Application |
SPP can be synthesized through a series of chemical reactions, beginning with the reaction of ethyl acetoacetate and aniline to form ethyl-3-phenyl-2-pyrazine-2-carboxylate. This intermediate is then reacted with hydrazine hydrate to produce (S)-3-Phenyl-2-(pyrazine-2-carboxamido)propanoic acid. |
| Future Directions |
Future research should focus on further elucidating the exact mechanism of action of SPP and its potential therapeutic applications in the treatment of type 2 diabetes, obesity, cancer, and other metabolic diseases. Additionally, further research should be done to explore the potential synergistic effects of SPP with other drugs. Other potential future directions include the development of SPP-based formulations for improved pharmacokinetics and pharmacodynamics, as well as the exploration of its potential applications in the treatment of other diseases. Finally, further research should be done to understand the potential toxic effects of SPP. |
Search 
+86 21 5895 0110 
